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LETTER TO THE EDITOR
Cefepime-induced encephalopathy
The most common adverse event of cefepime on
the central nervous system is seizure.1 Cefepime
induced encephalopathy, however, has been only
rarely reported.2,3
A 60-year-old diabetic patient with end stage
renal disease on hemodialysis was admitted with
left pleuritic chest pain and productive cough. He
was afebrile and hemodynamically stable, with
a systolic apical heart murmur, bilateral basal
lung crackles, and hepatomegaly. Laboratory data:
Hemoglobin 10.4 g/dl, Hematocrit 32%, WBCs
11000/mm3, PMN’s 91%, creatinine 10.9mg/dl and
BUN 64 g/l. Chest ﬁlm showed right middle lobe
inﬁltrates and cefepime (2 g/d) was started em-
pirically. Five days later, the patient started to
show confusion, have visual and auditory hallu-
cinations, and agitation with no focal deﬁcit on
physical examination. These neurological symp-
toms did not improve upon further dialysis over two
days; cefepime was then stopped. Within one day,
he started to improve, and two days later, he re-
turned to his baseline level of mental status. Upon
re-interviewing his wife and reviewing his medical
record, he was found to have had hallucinations and
confusion after taking ceftazidime, a year earlier.
Cephalosporin induced neurotoxicity has been
reported with ceftazidime, ceftriaxone, and
cefuroxime.4–6 The main predisposing factors are
pre-existing CNS abnormalities and renal impair-
ment with excessive dosing of the antibiotic.7
Our patient was given two grams of cefepime
daily based on recommendations of Gilbert et al.8
He developed confusion, hallucinations and agi-
tation, which progressed over one week despite
intensiﬁcation of hemodialysis and the absence
of electrolyte disturbances. Cefepime was then
stopped due to circumstantial evidence and the
previous occurrence of hallucinations with cef-
tazidime the year before. A CT scan of the brain
was not requested due to the lack of focal motor
or sensory deﬁcit, and an EEG was not carried out
because of the rapid clinical improvement after
stopping cefepime.
Neurotoxicity of cefepime has been reported
before and the spectrum of manifestations has
been broad including: confusion, hallucinations,
agitation, convulsions, tremor, delirium and coma
(Table 1). The latency of neurotoxicity, which is the
period between the start of cefepime treatment
and neurologic manifestations, varied between
one and ten days, and all neurological symptoms
regressed within two to seven days after stopping
the antibiotic infusion. Almost all patients affected
have had renal failure and the dose of cefepime
was relatively high for the level of renal failure.
The newer Sanford guides to antimicrobial therapy
(2001 to 2003) suggest a smaller dose of cefepime
according to the creatinine clearance.11 Thus, if a
patient on cefepime develops neurological symp-
toms, drug neurotoxicity should be considered.
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Table 1 Cases of cefepime induced neurotoxicity reported in the literature.
Study Year Age
(Year)
Sex Cefepime
dose
RF Number
of cases
Clinical ﬁndings Diagnosis Latency
(days)
Treatment
Fishbain et al.2 2000 74 F 2 g/24 h Yes 1 Confusion,
delirium, coma
EEG*, drug
level
4 D/C AB
Jallon et al.3 2000 57—91 7M/12F 2—6 g/24 h Yes 19 Confusion,
hallucination
EEG* 1—7 D/C AB
Martinez-Rodriguez
et al.6
2001 54—86 3M/3F 1—2 g/24 h Yes 6 Agitation,
confusion,
myoclonus,
EEG* 1—10 D/C AB,
Clonazepam,
phenytoin
Chetaille et al.9 1997 F 3 g/24 h Yes 1 Confusion,
convulsion
EEG** D/C AB
Dixit et al.10 2000 44/28 M/F 2 g/24 h Yes 2 Confusion,
tremor,
hyperreﬂexia,
seizure
EEG*** 1 D/C AB
M: male, F: female, h: hour, *: triphasic wave encephalopathy, **: irritative state, ***: continuous generalised sharp wave with slow activity, RF: renal failure,
D/C: discontinuation of drugs, g: grams, h: hour, AB: antibiotic.
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